ACP
BCRX icon

Acuta Capital Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Acuta Capital Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-50,600
Closed -$223K – 57
2016
Q3 		$223K Buy
+50,600
New +$202K 0.08% 58

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Acuta Capital Partners's BCRX Position: Q4 2020 in Review

Acuta Capital Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2020, closing a stake of 660,000 shares — an estimated $2.27M sold.

Acuta Capital Partners first reported a position in BCRX in Q3 2015 and held it in 13 quarters. The position peaked at $9.75M in Q4 2019. 177 funds tracked by Wall St. Rank hold BCRX as of Q4 2020.

  • Acuta Capital Partners reported no remaining BioCryst Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Acuta Capital Partners sold 660,000 BioCryst Pharmaceuticals shares in Q4 2020, an estimated $2.27M.
  • Acuta Capital Partners first reported a position in BioCryst Pharmaceuticals in Q3 2015 and held it in 13 quarters.
  • Acuta Capital Partners's BioCryst Pharmaceuticals position peaked at $9.75M in Q4 2019.
  • 177 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2020.

Based on Acuta Capital Partners's 13F filing for Q4 2020, filed 16 Feb 2021.